Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945177 | 0.92 | HDAC1 (0.41) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL2943251 | 0.88 | PPARG (0.43) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL2943244 | 0.88 | FSCN1 (0.40) | PPARGFSCN1HDAC1HDAC6HDAC3 | |
| SCHEMBL1684170 | 0.88 | FSCN1 (0.38) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL1684171 | 0.88 | FSCN1 (0.38) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL4805488 | 0.87 | FSCN1 (0.39) | PPARGFSCN1HDAC1HDAC6HDAC3 | |
| SCHEMBL2945087 | 0.87 | PPARG (0.42) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL2945250 | 0.86 | GABRA1 (0.43) | PPARGFSCN1PTGDR2 | |
| SCHEMBL4804098 | 0.86 | ALDH1A1 (0.42) | PPARGFSCN1HDAC1HDAC6HDAC8 | |
| SCHEMBL4804543 | 0.86 | FSCN1 (0.39) | PPARGFSCN1HDAC1HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | claimed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | claimed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | claimed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2011041512-A2 | COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES | EMORY UNIVERSITY (US) | 2011-04-07 | — | — | WO | disclosed |
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1558611-B1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368571-B2 | HIV-Integrase inhibitors, pharmaceutical compositions and methods for their use | PFIZER INC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7135482-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147547-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | IMPDH1, POLA1, POLB | PPARG 3118/4885FSCN1 4789/4885HDAC1 13/4885 |
| US-20070004768-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | PPARG 2978/4885FSCN1 4800/4885HDAC1 31/4885 |
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | PPARG 2781/4885FSCN1 4791/4885HDAC1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.